Decisión del Panel Administrativo nº D2020-2149 of WIPO Arbitration and Mediation Center, November 20, 2020 (case Teva Pharmaceutical Industries Limited v. Neeraj Manchanda, Kohinoor Medical Associates PA)

• Resolution Date: November 20, 2020
• Issuing Organization: WIPO Arbitration and Mediation Center
• Decision: Transfer
• Dominio: Generic Domains

WIPO Arbitration and Mediation Center

ADMINISTRATIVE PANEL DECISION

Teva Pharmaceutical Industries Limited v. Neeraj Manchanda, Kohinoor Medical Associates PA

Case No. D2020-2149

1. The Parties

Complainant is Teva Pharmaceutical Industries Limited, Israel, represented by SILKA AB, Sweden.

Respondent is Neeraj Manchanda, Kohinoor Medical Associates PA, United States of America (“United States”).

2. The Domain Name and Registrar

The disputed domain names [ajovydosing.com] and [copaxonedosing.com] are registered with GoDaddy.com, LLC (the “Registrar”).

3. Procedural History

The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on August 14, 2020. On August 14, 2020, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain names. On August 17, 2020, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain names which differed from the named Respondent and contact information in the Complaint. On August 18, 2020 the Center notified the Suspension of the proceedings before commencement. On September 10, 2020, by petition of Complainant, the proceedings were reinstituted.

The Center sent an email communication to Complainant on September 14, 2020 providing the registrant and contact information disclosed by the Registrar, and inviting Complainant to submit an amendment to the Complaint. Complainant filed an amendment to the Complaint on September 21, 2020.

The Center verified that the Complaint together with the amendment to the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy” or “UDRP”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).

In accordance with the Rules, paragraphs 2 and 4, the Center formally notified Respondent of the Complaint, and the proceedings commenced on September 22, 2020. In accordance with the Rules, paragraph 5, the due date for Response was October 12, 2020. Respondent did not submit any response. Accordingly, the Center notified Respondent’s default on October 13, 2020.

The Center appointed David Perkins as the sole panelist in this matter on October 29, 2020. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.

4. Factual Background

4.A Complainant

4. A.1 Complainant, which was established in 1901, is today a leading global pharmaceutical company. It is one of the world’s largest generic medicines producer, leveraging a portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines...